AI-generated summary
The authors reviewed the FDA 510(k) database to identify home-use photobiomodulation devices cleared for androgenetic alopecia and compared 13 commercially available devices by design, features, and clinical evidence. They report that no head-to-head studies compare these devices' efficacy, and that long-term, high-quality studies in diverse populations are lacking. They describe the safety profile as excellent and the evidence for efficacy as mounting.
- Who or what was studied
- Adults with androgenetic alopecia, as addressed by home-use photobiomodulation devices
- Limits stated in the abstract
- The abstract states that head-to-head comparisons are absent and that long-term, high-quality studies in diverse populations are lacking.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Androgenetic alopecia, Light-emitting diode, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.